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Recent advances in synthetic and medicinal
chemistry of phosphotyrosine and phosphonate-
based phosphotyrosine analogues
Nikolai Makukhin and Alessio Ciulli *
Phosphotyrosine-containing compounds attract significant attention due to their potential to modulate
signalling pathways by binding to phospho-writers, erasers and readers such as SH2 and PTB domain
containing proteins. Phosphotyrosine derivatives provide useful chemical tools to study protein
phosphorylation/dephosphorylation, and as such represent attractive starting points for the development
of binding ligands and chemical probes to study biology, and for inhibitor and degrader drug design. To
overcome enzymatic lability of the phosphate group, physiologically stable phosphonate-based
phosphotyrosine analogues find utility in a wide range of applications. This review covers advances over
the last decade in the design of phosphotyrosine and its phosphonate-based derivatives, highlights the
improved and expanded synthetic toolbox, and illustrates applications in medicinal chemistry.
Introduction
Reversible protein phosphorylation is one of the most
important cellular events as it plays a crucial role in signal
transduction, activation or deactivation of genes transcription,
and on/off control of enzyme activity.1,2 Although protein
tyrosine phosphorylation occurs at low level compared to serine
or threonine phosphorylation, protein tyrosine phosphorylation
is vital for cell growth regulation, mitogenesis, metabolism and
apoptosis.3 The main steps of this pathway involve the
phosphorylation of tyrosine by protein tyrosine kinases (PTKs),
recognition of pY residues by proteins containing pY-binding
modules such as Src homology 2 (SH2) or phosphotyrosine
binding (PTB) domains, and removal of a phosphotyrosine
phosphate group by protein tyrosine phosphatases (PTPs).
Misfunctions in each of these steps have been linked to
numerous diseases such as inflammation, diabetes, cancer and
metabolic and autoimmune diseases.4–8
The significance of protein tyrosine phosphorylation
motivates the development of pY containing peptides and
small-molecule derivatives that can mediate protein–protein
interactions or serve as substrate/product mimetics, thereby
providing useful chemical tools to study the roles of
individual proteins involved in signalling pathways or
pathways contributing to diseases.9–13 Such compounds can
also provide useful tools for biophysical protein
characterization,14 for monitoring enzyme activity,15,16 and as
antigens for raising antibodies.17,18 Moreover, synthetic pY-
containing peptides have been used to obtain co-crystal
structures of protein–peptide complexes,11,14,19,20 revealing
structural insights into substrate recognition and specificity
of the enzymes, and guiding structure-based drug design.
Additionally, the immobilisation of pY on agarose gel has
allowed the purification of human immunoglobulin G (IgG)21
and pre-miRNA (MicroRNA)-29 (ref. 22) from human plasma
via mimicking the natural interactions. Due to hydrolysis of
the phosphate group by PTPs, pY-containing macromolecules
have found interesting applications in phosphatase-
instructed self-assembly to form higher-order
nanostructures,23,24 which can be used in the design of
probes for biomedical imaging applications25 and enhanced
photoacoustic imaging of tumours.26
Phosphotyrosine residues and analogues are challenging
functional groups for drug design because of their negative
charge at physiological pH and the enzymatic lability of the
phosphate group. The first limitation can be solved by applying
a prodrug approach.27 The improvement of the metabolic
stability in the presence of PTPs has been a challenging task
for medicinal chemistry and a whole discipline has arisen
devoted to the design of pY mimetics.28,29 After significant
research phosphonodifluoromethyl phenylalanine (F2pmp) was
found to be one of the most promising physiologically stable
pY analogues. Recently, the F2pmp scaffold was successfully
employed in the discovery of cell-permeable PTP inhibitors30–32
and for affinity purification of SH2 proteins from cell lysates.33
Targeting of phosphotyrosine-binding domains by small
molecules has attracted particular attention over the last
decades, and is now seeing a renaissance as a promising
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approach in drug discovery.6,9,34 The syntheses of pY
containing molecules and pY mimetics are well established
and have been previously reviewed.35,36 Here we summarise
approaches developed over the last ten years and highlight
methods not previously discussed.
Structural basis of phosphotyrosine
recognition
Phosphotyrosine is ‘read’ by cellular proteins binding tightly
to the pY side chain phosphate group with high specificity.
Fig. 1 Structural basis of molecular recognition specificity of pY-reader domain interactions. Left: Architecture of the reader domain, with
secondary structure elements labelled. Right: Zoom-in on the binding mode and hydrogen bond interactions between the pY-substrate peptide
and the domain pY-binding pocket. A) SH2 domain recognition. Crystal structure of SOCS2 in complex with phosphorylated EpoR peptide
(ASFEpYTILDPS-amide, PDB code: 6I4X).14 Only the SH2 domain of SOCS2 is shown. B) PTB domain recognition. Crystal structure of the IRS-1 PTB
domain bound to the juxtamembrane region of the insulin receptor (LYASSNPApY, PDB code: 5U1M).42 C) PTP domain recognition. Crystal
structure of PTP-1B catalytically inactive mutant C215S in complex with nephrin peptide (AWGPLpYDEVQM, PDB code: 4ZRT).43
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However, the structural details of the molecular recognition
differ depending on the domain being used.
The SH2 domain is a structurally conserved reader domain
whose general domain architecture and pY recognition mode
are well understood following decades of studies since its first
discovery.37–39 The SH2 domain comprises multiple β-sheets
flanked by two α-helices (Fig. 1A, left), and it has two distinct
regions. The first region, highly conserved within the family,
contains the pY-binding pocket. This pocket is located at the
N-terminal region between the first α-helix and the central
β-strand where the pY phosphoryl group interacts with two
positively charged Arg residues and forms additional hydrogen
bonds with Ser or Thr residues (Fig. 1A, right). Of note, this is
not the case with all SH2 domains. For example, the SH2
domains of STAT proteins can engage the phosphate group
with a single Arg residue.40 The second part of the domain,
defined between the central β-strand and the C-terminal
α-helix, provides specificity for substrate binding via
interactions with residues C-terminal to pY in the peptide
binding epitope. The recognition mode of SH2 domains for pY
partner proteins thus involve anchoring of pY to accommodate
the flanking regions of the peptide on the domain surface. Our
group recently solved co-crystal structures of the SH2-
containing E3 ligase substrate receptor subunit suppressor of
cytokine signalling 2 (SOCS2) in complex with pY-modified
peptides from substrates growth hormone receptor (GHR) or
erythropoietin receptor (EpoR) (Fig. 1A).14 The structure
illustrates the canonical SH2-pY recognition mode, and
identifies the C-terminus of the peptide as fitting snugly
through the C-terminal hydrophobic cavity of the domain,
forming hydrogen bonds from its backbone amide bonds along
with hydrophobic interactions.
PTB domains represent another modular unit that recognize
pY-containing proteins. The overall structure of the domain and
the substrate recognition features are different from the SH2
domain. PTB domains have a conserved fold consisting of two
central orthogonal β-sheets (made of seven β-strands overall),
capped by a carboxy-terminal α-helix (Fig. 1B, left).39 Unlike SH2
domains, PTB domains bind to partner proteins by recruiting
amino acids N-terminally to the pY residue. They recognise an
NPXpY sequence motif, and the pY binding pocket is typically
solvent-exposed. Of note, a phosphorylated tyrosine residue is
not required for high-affinity binding to all PTB domains and in
some cases even inhibits it.37 However, mutations at that
position, for example Y-to-E or Y-to-F, typically abolish the
protein–protein interaction and inhibit biological activity.41 The
crystal structure of the PTB domain of the insulin receptor
substrate 1 (IRS-1) bound to a phosphorylated peptide from the
juxtamembrane region of the insulin receptor (IR) illustrate
these recognition features (Fig. 1B).42 pY forms salt-bridge
hydrogen bonds with two Arg residues and with a network of
water molecules (Fig. 1B, right). The N-terminus stretch of the
peptide forms a β-strand that fits snugly into a groove between
the α-helix and the β5-strand of the domain (Fig. 1B, left).
Protein tyrosine phosphatases (PTPs) are a third class of
proteins that recognize pY-containing substrates in order to
catalyse their dephosphorylation. This catalytic process relies
on the presence of a cysteine residue located in the PTP
phosphate binding site, defined by the sequence HCX5R.
37
This motif is strictly conserved among the PTP family
members. The stabilization of the pY phosphate group is
achieved by an Arg residue, that together with the backbone
amide nitrogens of the CX5R motif forms a ‘crown-like’
coordination mode (Fig. 1C).44 Selectivity for pY over
phosphothreonine (pT) and phosphoserine (pS) is established
by the depth of the active site and by the presence of specific
aromatic residues at the mouth of the pocket. While the
catalytic mechanism of PTPs is well established, substrate
specificity remains elusive for numerous phosphatases. To
this end, pY-containing peptides provide useful chemical
tools to study the protein–protein interaction and gain
insights into substrate specificity. The crystal structure of
PTP-1B protein bound to a phosphorylated peptide from
substrate nephrin illustrate these recognition features
(Fig. 1C, left).43 The nephrin peptide binds to PTP-1B in a
canonical fashion with its pY residue anchored tightly by
hydrogen bond interactions, and it phenyl group
“sandwiched” via π-stacking interactions. The nephrin
peptide makes additional hydrogen bond interactions beyond
pY along the backbone (Fig. 1C, right).
The structures presented in Fig. 1 are representative
examples highlighting the recognition of the pY group by its
reader domains. Regions flanking the pY residue are also
important for the recognition of pY-containing substrates by
these reader proteins, and as such they contribute to
substrate specificity as reviewed previously.37,39
Notwithstanding the complexity of the molecular recognition
beyond pY, the structures illustrate the significance of the
double-negative charge and the ester oxygen of the phosphate
group for high binding affinity of pY and pY-mimetic ligands.
These observations were important to the development of
phosphonate-based phosphotyrosine mimetics and led to a
discovery of F2pmp.
28,29 Importantly, the –CF2– group has
larger size than the ester –O– group, and the sum of the bond
lengths within the fragment P–CF2–C (P–CF2 bond plus CF2–
C bond) is greater than for the P–O–C fragment (P–O bond
plus O–C bond). These structural features can affect the
ligand binding mode and lead to a loss in binding energy.
However, during the ligand design this loss in the binding
affinity can be compensated and so recouped by optimizing
the rest of the molecule.
Advances in the synthesis of
phosphotyrosine-containing
compounds
Over the past decade, several phosphotyrosine building
blocks and phosphotyrosine phosphonate-based mimetics
have become commercially available,45 and are widely
employed in peptide synthesis20,30,46 (Fig. 2). This represents
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compounds remain relatively expensive and mainly suitable
only for solid phase peptides synthesis (SPPS). Currently
Fmoc-Tyr(PO3H2)-OH is rarely used in peptide chemistry
because of the synthetic problems caused by unprotected P–
OH groups.45 These problems could be solved by employing
bis-protected di-O-benzyl/methyl phosphotyrosine building
blocks. However, the undesired removal of the methyl or
benzyl groups by piperidine during Fmoc-SPPS has been
observed.47 O-Phosphate monodealkylation could be
decreased by utilizing the non-nucleophilic base, DBU, in a
concentration of 2% in DMF for Fmoc-deprotection instead
of piperidine.47 Despite the presence of a free P–OH group,
Fmoc-Tyr(PO(OBzl)OH)-OH is the most frequently used
building block. Slow and incomplete incorporation of Fmoc-
Tyr(PO(OBzl)OH)-OH during peptide assembly can be
resolved by tuning reaction conditions.48 Fmoc-
Tyr(PO(NMe2)2)-OH has recently become commercially
available facilitating peptide synthesis and allowing mild
conditions for phosphate deprotection.
The custom synthesis of the pY core is based on the
phosphorylation of tyrosine and typically achieved using
three traditional methods (Scheme 1, paths A–C).35 The
chemistry of these transformations remained virtually
unchanged for decades, yet a few modifications were
recently introduced.
The first approach is based on introducing the phosphate
group using inorganic reagents, POCl3 or P2O5
(Scheme 1, path A). Regardless of harsh conditions, these
methods were recently utilized for the synthesis of Fmoc-
Tyr(PO3H2)-OH,
23,49,50 O-phospho-3,5-difluorotyrosine51 and
cyclosaligenyl phosphodiester moiety (Fig. 3A).52 Chu et al.
proposed the cyclosaligenyl phosphodiester (cpY) as a novel
phosphotyrosine mimetic and showed that cpY-containing
dipeptides inhibited the interaction between SLAM (signaling
lymphocytic activation molecule) and SH2-containing SAP
(SLAM-associated protein).52 SLAM and SAP are involved in
immune cell interactions and considered as potential targets
for autoimmune disease therapy. Among all obtained
dipeptides in this study, Fmoc-cpY-Asp-NH2 (Fig. 3B) showed
the most potent inhibitory activity with IC50 = 17 μM in a cell-
free assay system. Interestingly, it was observed that not only pY
but also a Fmoc group was required for binding of the
synthesized dipeptides, as inhibitor activity was lost after Fmoc
group removal.52
The second method is phosphorylation with
phosphorohalidates in the presence of base
(Scheme 1, path B). Due to the low reactivity of
phosphorochloridates, the addition of the catalyst (e.g. DMAP
or Lewis acids) and/or prolonged reaction time are often
required to facilitate the reaction. The latest examples of this
method were realised in the synthesis of O-diethylphospho
L-tyrosine N-carboxyanhydride (a monomer for the production
poly(L-phosphotyrosine) polymer)53 and in the synthesis of
the precursor for visible light-induced borylation.54 As far as
selectivity is concerned, recently Murray and co-workers
reported the site-selective phosphorylation of Tyr in the
presence of Ser and Thr residues in peptides using o-xylenyl
phosphoryl chloride,55 which makes this method valuable for
a post-synthetic global phosphorylation approach. The
selectivity was achieved by employing 2-aryl-4-DMAP-N-oxide
as a catalyst and pempidine (1,2,2,6,6-pentamethylpiperidine)
as a base (Scheme 2). Xylenyl phosphate can be subsequently
deprotected by hydrogenolysis (H2, Pd/C).
A recent improvement in the phosphorohalidates
approach allows to generate the dialkyl phosphoriodidate in
situ from phosphite and iodine (Scheme 1, path D). This
relatively inexpensive and convenient method was utilized for
the introduction of ethyl and allyl protected phosphates into
the tyrosine core.56–58 The suggested mechanism involves the
Arbuzov reaction of alkyl phosphite with iodine followed by
direct phosphorylation of phenol in the presence of base.58
The third most commonly used approach for tyrosine
phosphorylation is based on phosphitylation using
phosphoramidites in the presence of an activator, followed
by oxidation of P(III) to P(V) (Scheme 1, path C). A well-
established protocol includes tetrazole as activator and
oxidation with t-butyl hydroperoxide. Recently, this
methodology was successfully applied to the development of
probes for monitoring PTPs activity. van Ameijde et al.
Fig. 2 Commercially available phosphotyrosine (A) and
phosphonodifluoromethyl phenylalanine (F2pmp) (B)-based building blocks.
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designed an assay to monitor dephosphorylation of
3-nitrophosphotyrosine-containing peptides.59 In that assay,
phosphatase activity is measured via formation of
3-nitrotyrosine residue that can be detected by the specific,
sequence-independent anti-nitrotyrosine antibody HM11
(Fig. 4A). Another PTP activity probe, 1, was suggested by
Choi et al. and based on a fluorescence change upon
dephosphorylation (Fig. 4B).15 Changes on the emission
intensity were explained by tyrosine-induced quenching of
coumarin fluorescence, albeit via a still elusive mechanism.
Tyrosine phosphorylation by dibenzyl
diisopropylphosphoramidite was used in the development of
non-peptide Grb2-SH2 ligands.60 Growth factor receptor-
bound protein 2 (Grb2) is an adaptor protein between cell
membrane receptors and cytoplasmic kinases and has been
associated with breast and bladder cancers. Grb2 inhibition
blocks the human epidermal growth factor receptor 2 (HER2)
activation and therefore is pursued as a drug discovery
strategy.61 Using molecular modelling and NMR-guided
approach, Grb2-SH2 binder 2 (Fig. 4C) was developed and
shown to block Grb2 substrate binding with IC50 = 56 μM,
and to inhibit the proliferation of the HER2-positive MCF7
breast cancer cell line (IC50 = 100 μM), with no effect on
fibroblasts or HER2-negative breast cancer cell lines.60 A
similar reaction between tyrosine and bis(o-nitrobenzyl)-
diisopropylphosphoramidite was utilised for the synthesis of
bis(o-nitrobenzyl)-phosphotyrosine, which was used for the
modification of a suppressor tRNACUA for the in vitro
synthesis of proteins with predetermined positions of
phosphorylated tyrosine residues.62
In phosphoramidite chemistry, 1H-tetrazole is most
commonly used as activator. Unfortunately, tetrazole exhibits
explosive properties and is no longer commercially available
in a solid form or an effective concentration due to limited
Scheme 1 Synthetic strategies for the synthesis of phosphotyrosine. Available methods to synthesize a pY building block are shown. Methods
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solubility. Several alternative activators (Fig. 4D), such as
DCI, ETT, BTT have been developed, which increase the rate
and efficiency of phosphoramidite coupling, and are
employed in the synthesis of nucleotides. Recently this
experience was translated into the synthesis of
phosphotyrosine derivatives.63,64 Of note, the use of DCI
allowed to produce Fmoc-Tyr(PO(OBzl)2)-OH in multi-gram
scale with an excellent yield.14
An interesting example of the use of the phosphoramidites
technique was demonstrated by Albers and Hedberg in the
preparation of building block 3 (Fig. 4E) for Fmoc SPPS of
peptides containing phosphocholinated residues.65 In this
work, the authors employed 5-(benzylthio)-1H-tetrazole (BTT) as
the activator. Phosphocholination is a recently discovered post-
translational modification important for Legionella pneumophila
pathogenesis.66 Synthetic phosphocholinated peptides are
promising tools for studying of phosphocholination/
dephosphocholination pathways and raising epitope-specific
antibodies for phosphocholinated proteins.
Using a strategy that is conceptually related to the
phosphitylation approach described above
(Scheme 1, path C), a new efficient one-pot synthesis of
protected phosphoamino acids was developed.67 One
example of products achieved with this route is Fmoc-
Tyr(PO(OBzl)OH)-OH (Scheme 3). This compound was
previously synthesised in a multistep procedure that included
the protection of the carboxylic group,68 a step not required
by the new method.
In the last decade a new trend in the use of
aminophosphoryl chlorides in the synthesis of
phosphotyrosine has emerged (Scheme 1, path E). Originally
reported by Chao and co-workers in 1995,69 a method for
tyrosine phosphorylation with commercially available
bis(dimethylamino)phosphoryl chloride did not receive
much attention until recent years. The method allows to
introduce N,N-dialkyldiamide-type phosphate protecting
group, which can be easily converted into the corresponding
phosphate under mild conditions (method A: 2M HCl/
dioxane = 1/1 in 6 h;69 method B: 0.04 M HCl (pH 2) in 36
h).70 This approach was successfully employed in the
synthesis of a spy molecule for 19F NMR displacement
assays to study pY-peptides binding to SOCS2,14 as well as
to obtain inhibitors of STAT3 protein (Fig. 5A).71 The signal
transducer and activator of transcription 3 (STAT3) is an
attractive cancer therapeutic target due to its hyperactivation
in many human cancers.8 STAT3 upregulation stimulates
cell proliferation and apoptosis evasion in cancer cells.
STAT3 plays a key role in cell signalling from cell
membrane receptors into the nucleus. Upon receptor
activation by cytokine or growth factor, STAT3 is recruited
from the cytoplasm via interactions of the STAT3 SH2
domain with specific pY sites of the receptor. The docked
Fig. 3 Cyclosaligenyl phosphotyrosine mimetic targeting SAP–SLAM
interactions. A) Synthesis of the Fmoc-cpY building block.52 B)
Chemical structures of the SAP–SLAM inhibitor Fmoc-cpY-Asp-NH2.
52
Scheme 2 Site-selective phosphorylation of a tyrosine-containing peptide.55
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STAT3 is then phosphorylated causing its dimerization and
nuclear translocation. Since the dimerization of STAT3 is
critical for its activation, targeting the STAT3-SH2 domain
by small molecules, which block its interaction with
receptors and homodimerization, is a promising approach
for therapeutic intervention. To design STAT3 inhibitors,
Shahani et al. fused the structure of previously described
inhibitor ISS-610 with a peptide motif derived from the
gp130 receptor known to bind the STAT3 SH2 domain.71
The synthesised compound 4 (Fig. 5A) showed high affinity
to STAT3 (KD = 900 nM, by SPR), disrupted the STAT3-gp130
phosphopeptide interaction (IC50 = 5 μM) and inhibited
STAT3 homodimerization in cells.71 However, cell
proliferation assay showed only 50% suppression in cell
viability of human prostate, pancreatic and breast cancers
probably due to poor cell permeability and stability of the
inhibitors.
The aminophosphoryl chloride approach was used by
Miccoli et al. for the preparation of aryloxy triester
phosphoramidate prodrugs of ISS-610 obtained by treatment
of appropriate tyrosine derivative 5 with (chloro(naphthalen-
1-yloxy)phosphoryl)-L-alaninates using triethylamine as a base
(Fig. 5B).72 This was the first application of the aryloxy
phosphoramidate prodrug technology for pY-containing
molecules. This technology (so-called ProTide) is widely used
in the synthesis of nucleotide prodrugs, including several
FDA-approved drugs and clinical candidates, such as
sofosbuvir and remdesivir.73 In the proposed aryloxy
phosphoramidate prodrug approach, the negative charge of
the phosphotyrosine is masked by a naphthyl group and an
amino acid ester to increase cell membrane penetration.
Inside cells the masking groups are cleaved by two
consecutive enzymatic activities: first an esterase and second
a phosphoramidase activity (Fig. 5C). The choice of the
naphthyl rather than phenyl as the aryl motif was critical
Fig. 4 Recent applications and advances in the phosphoramidite approach. A) Strategy of the 3-nitrophosphotyrosine based assay for
phosphatase activity measurement.59 B) Fluorescence probe 1 for monitoring the phosphatase activity.15 C) Grb2-SH2 domain inhibitor 2.60 D)
Structure of activators alternative to 1H-tetrazole. E) Synthesis of phosphocholinated tyrosine building block 3 for Fmoc SPPS.65
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because naphthyl is a better leaving group than phenol,
which prevents the release of the phenol of the
phosphotyrosine during metabolism.72
Wu and co-workers gave a new impetus to the
aminophosphoryl chloride approach by introducing a group
assisted purification (GAP) strategy for the synthesis of pY
Fig. 5 Aminophosphoryl chloride approach in phosphotyrosine synthesis. A) Use of ClP(O)(NMe2)2 in the synthesis of STAT3 inhibitor 4.
71 B)
Synthesis of aryloxy phosphoramidate prodrugs of ISS-610 (a STAT3 inhibitor).72 C) Mechanism of in vivo metabolism of the aryloxy
phosphoramidate prodrug. D) Group assisted purification (GAP) synthesis of a phosphotyrosine-containing dipeptide.74
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and pY-containing peptides.74 GAP chemistry involves the
introduction into the molecule of special auxiliaries which
generate a compound of adequate solubility. The compound
generated is soluble in several solvents (usually DCM, THF,
MeOH), but has poor solubility in petroleum solvents and
their cosolvents. That is why the desired product can be
isolated by a simple filtration and washing. In the suggested
approach tyrosine was phosphorylated by 2-chloro-1,3-
diphenyl-[1,3,2]diazaphospholidine 2-oxide in the presence of
triethylamine to introduce the GAP auxiliary.74 The proposed
GAP concept allows solution phase peptide synthesis without
using chromatography or recrystallization (Fig. 5D).
Furthermore, N,N- diphenylethylenediamine auxiliary can be
recovered for re-use. It was suggested that group assisted
purification method can complement SPPS, especially for
large-scale peptide synthesis. For example, this approach was
successfully applied for the synthesis of biphalin peptides.74
A distinct approach to the synthesis of pY derivatives is
based on dialkyl phosphites and can be considered as an
extension of the Todd reaction (Scheme 1, path F). It is
postulated that tyrosine is phosphorylated by dialkyl
halogen phosphate generated in situ from dialkyl
phosphite and tetrabromo- or tetrachloromethane in the
presence of base. This approach was proposed by
Szardenings et al. for the preparation of phosphotyrosine
mimetics using CBr4/HP(O)(OEt)2/NEt3.
75 Recently this
method was used in the synthesis of activity-based probes
for protein tyrosine phosphatase, with minor alterations.16
The probes consist of a 3-fluoromethylphosphotyrosine
warhead connected through a PEG linker to biotin, which
served as reporter unit (Fig. 6A). According to the
proposed mechanism, after phosphatase hydrolysis the
probe undergoes elimination of the fluorine yielding an
intermediate which reacts with nucleophilic residues of
PTP (Fig. 6B). After formation of a covalent bond the
enzyme can be detected using anti-biotin antibody.
3-Fluoromethylphosphotyrosine warhead was incorporated
into peptides that were used to study the substrate
specificity of PTPs.16 Of note, the use of dialkyl
phosphites allows a selective phosphorylation of the
phenolic hydroxyl group (Fig. 6C).16
Fenton et al. reported the Lewis acid catalyzed
phosphorylation with pyrophosphates (Scheme 1, path H).76
Titanium(IV) tert-butoxide was found to be the most effective
catalyst for the reaction of Boc-Tyr-OMe with
tetrabenzylpyrophosphate (Scheme 4). Other pyrophosphates
with methyl, ethyl, allyl, and o-nitrobenzyl protecting groups
are synthetically available and might serve as
phosphorylating agents.
In contrast to the above-described methods for pY
synthesis based on tyrosine phosphorylation, Wang et al.
demonstrated a new strategy – palladium-catalyzed
N-quinolylcarboxamide directed arylation of the unactivated
β-C(sp3)–H bonds of alanine (Scheme 1, path G).77 Phthaloyl
alanine reacts with (4-iodophenyl)diethylphosphate under the
developed conditions providing the desired pY-containing
compound in good yield (Scheme 5). The 8-aminoquinoline
auxiliary group is essential for the Pd-catalyzed C(sp3)–H
bond activation and the use of silver trifluoroacetate in
1,1,2,2-tetrachloroethane (TCE) at room temperature allows
to perform mono-selective arylation of alanine. Interestingly,
the reaction is tolerant to both water and air. The starting
phthaloyl alanine bearing 8-aminoquinoline group was
obtained in three steps from L-alanine. The 8-aminoquinoline
auxiliary can be cleaved under mild conditions by treatment
with LiOH–H2O2.
77
Although this approach has been demonstrated only for
generating of a pY core group, it can be readily expanded to
Fig. 6 Recent applications of the dialkyl phosphite approach. A) PTP
activity-based probes.16 B) Proposed mechanism for PTP trapping. C)
Selective phosphorylation of the phenolic hydroxyl group by
diallylphosphite.16
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the synthesis of different pY mimetics using the
corresponding aryl iodides.
Advances in the synthesis of
phosphonate-based phosphotyrosine
mimetics
Hydrolysis of the pY phosphate group by PTPs is a key step
in cell signalling, but makes phosphotyrosine a liable
functional group in the design of SH2, PTB or PTP inhibitors.
Non-hydrolysable pY mimetics are thus well-established and
their synthesis has been reviewed.36 Among all developed
phosphonate-based phosphotyrosine mimetics, in the last
decade phosphonodifluoromethyl phenylalanine (F2pmp)
received much attention due to its structural features and
physicochemical properties, such as a similar pKa compared
to pY, and the presence of the methylene fluorine atoms,
which may mimic the hydrogen bond interactions of
phenolic oxygen with active site residues. Therefore, the
interest in F2pmp stimulates the ongoing development of
novel synthetic approaches to F2pmp derivatives (Scheme 6).
Fmoc-F2Pmp-OH is widely utilized in the synthesis of
F2Pmp-containing peptides and small molecules for use as
inhibitors against PTPs.12,30–32 Considering pY as a main
substrate for PTPs, it is a common strategy in the ligand
design to employ a nonhydrolyzable pY mimetic, such as
F2Pmp, which occupies the active site with the same binding
mode as pY. Introducing molecular diversity at C- and
N-terminal sides of F2pmp achieves high binding affinity and
selectivity by targeting specific flanking residues in the
pocket. Zhang et al. followed this logic in the development of
a potent and selective inhibitor for megakaryocyte protein
tyrosine phosphatase 2 (PTP-MEG2) (Fig. 7A).32 Ligand 6 was
synthesised using standard solid-phase Fmoc chemistry on a
Rink amide resin. Compound 6 inhibited PTP-MEG2 with
IC50 = 75 nM, showed more than 18-fold selectivity for PTP-
MEG2 over PTP1B and T-cell protein tyrosine phosphatase
Scheme 5 Palladium-catalyzed mono-arylation of the β-methyl group of alanine.77
Scheme 6 Synthetic strategies to the phosphonodifluoromethyl phenylalanine. Paths D–F have been discussed in the ref. 36. Colour scheme
represents the bond formation: C–F bond, green; Ar–CH2, red; CF2–Ar, blue.
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(TC-PTP), and exhibited no inhibition of any other tested
mammalian PTPs. The co-crystal structure of PTP-MEG2 with
inhibitor 6 revealed that F2Pmp fragment, as anticipated,
bound to the active site pocket of the enzyme making contacts
with residues in the pY recognition loop, P-loop and Q-loop
(Fig. 7B). At the same time 3-iodobenzoic amide moiety binds
to a hydrophobic groove created by Pro315, Phe319, Pro337,
and Phe556 residues, which are unique to PTP-MEG2
(Fig. 7B). These less conserved interactions were thought to
be responsible for the inhibitor selectivity and potency.
Furthermore, 3-bromo-4-methylbenzoic amide, homovanillic
amide and diaminopropionic acid linker make additional
contacts with the enzyme, contributing to the high binding
affinity. Targeting PTP-MEG2 attracts considerable attention
as new approach for the treatment of type 2 diabetes due to
its negative regulation of insulin signalling. Indeed, the
developed inhibitor improved insulin sensitivity and glucose
homeostasis in diet-induced obese mice.32 Interestingly,
compound 6 showed efficient cellular and in vivo activity
despite the presence of a charged phosphonate group.
Recently, Pei with co-workers employed the F2pmp
scaffold in the design of cell-permeable bicyclic peptides
targeting PTPs.30,31 To obtain potent, selective and active
in vivo inhibitors of PTPs the authors fused two peptide
rings. One ring is a F2Pmp-containing cyclic peptide, which
is responsible for target binding. The other ring is a cell-
penetrating peptide contributing to cellular entry. For
example, molecule 7 (Fig. 7C) showed 16-fold selectivity for
PTP-1B (with IC50 = 30 nM) over TC-PTP and no inhibition
against a large panel of tested PTPs.31 Moreover, the authors
demonstrated that compound 7 efficiently entered human
cells A549 and inhibited PTP1B activity in vivo.
In recent years Fmoc-F2Pmp-OH has become commercially
available (Fig. 2), but it is still relatively costly. To address
this issue, Meyer and Köhn optimised Qabar's approach
(Scheme 6, path A) for a fast and efficient synthesis of Fmoc-
F2Pmp-OH.
78 This method is based on the copper(I) catalysed
reaction between phosphonodifluoromethyl-cadmium
bromide and Fmoc-Tyr(I)-OTMSE (Fig. 8A). CuBr was shown
as superior to CuCl in facilitating this transformation. The
final product can be obtained in gram scale.
A similar copper-mediated cross coupling of
phosphonodifluoromethyl-zinc bromide was employed to
make F2Pmp-containing building block 8, which was used for
the production of an affinity resin to enrich SH2 proteins
from cell lysates.33 To perform the inhibitor affinity
Fig. 7 Recent application of F2Pmp in drug design. A) Chemical structure of PTP-MEG2 selective inhibitor 6.
32 B) Crystal structure of PTP-MEG2
with inhibitor 6 (PDB code: 4GE6).32 C) Chemical structure of cell-permeable bicyclic peptide PTP1B inhibitor 7.31 D) Chemical structure of ligand
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purification, ligand 8 (Fig. 7D) was immobilized on NHS-
activated Sepharose. Following pull-down from cell lysates,
22 out of 55 SH2 proteins were enriched.
Ivanova et al. reported a new copper catalysed formation
of aryl difluoromethylphosphonates from iodonium salts and
TMSCF2PO(OEt)2 in the presence of CsF.
79 This methodology
was successfully applied to a synthesis of AcNH-F2Pmp-OMe
(Fig. 8B). Carrying out the reaction in a glovebox and
multistep preparation of the starting material make this
approach less attractive in comparison to traditional
methods.
Common methods for the synthesis of F2Pmp derivatives
involve the fluorination of corresponding ketophosphonates
with aminosulfur trifluorides or the introduction
difluoromethylated phosphonate group via copper-mediated
cross-couplings (Scheme 6, paths A, E and F).36 However,
these approaches are suboptimal because they are either
incompatible with numerous functional groups or use a large
excess of a toxic cadmium precursor BrCdCF2P(O)(OEt)2. To
overcome these drawbacks, Feng et al. proposed the
palladium-catalyzed difluoroalkylation of the commercially
available Boc-4-borono-L-phenylalanine methyl ester with
bromodifluoromethylphosphonate by using a catalytic system
consisting of Pd(PPh3)4, xantphos and K2CO3 in dioxane
(Fig. 8C).80 The choice of the ligand, base and solvent was
found to be crucial to achieve reaction efficiency.
4-Boronophenylalanine analogues are commercially available
or synthetically accessible. They can be readily synthesised
from 4-iodophenylalanine precursors or tyrosine derivatives
via triflates. In light of this, Feng's approach
(Scheme 6, path C) may allow not only to produce a broad
range of derivatives, but also to generate molecular matched
pairs useful to build structure–activity relationships (SAR) in
inhibitor development campaigns.
Fluorination of corresponding benzoylphosphonates was
one of the first approaches toward F2Pmp derivatives
(Scheme 6, path F).36 Recently Rademann and co-workers
demonstrated that α-ketophosphonates, and particularly
4-phosphonocarbonyl phenylalanine (pcF), can also be used
as photoactive enzymatically stable phosphotyrosine
mimetics targeting, deactivating and labelling
phosphotyrosine binding proteins.81–83 For example, pcF was
incorporated into the sequence of a STAT5 SH2 domain-
directed peptide, labelled with 5,6-carboxyfluorescein (CF) for
binding studies and protein detection.81 The resulting
peptide 5-CFGpcFLSLPPW-NH2 exhibited 20-fold reduced
binding affinity in comparison to a native phosphotyrosine-
containing peptide. Irradiation of this peptide at 365 nm
resulted in a formation of a triplet biradical intermediate 9 of
the benzoylphosphonate moiety leading to a covalent
modification of target proteins (Fig. 9A).81 Recognition by a
phosphotyrosine binding pocket allowed photo-crosslinking
with high specificity. This approach was utilised to pull-down
STAT5 from cell lysates using a similar pcF-containing, but
dual-labelled (carboxyfluorescein and biotin) STAT5-SH2-
binding peptide, and was applied to confirm selectivity of the
studied inhibitors.82
To integrate pcF into peptides, Horatscheck et al.
developed building block 10 for Fmoc SPPS (Fig. 9B).81
Compound 10 was obtained via Michaelis–Arbuzov acylation
of tribenzyl phosphite with the corresponding carboxylic acid
chloride. It is noteworthy that the authors produced the
monobenzyl phosphonate foreseeing a P–C bond cleavage of
the dialkyl acylphosphonate moiety by nucleophiles such as
piperidine during peptide synthesis. In addition, the
carboxylic acid was converted into its sodium salt to increase
the stability of the final product.
Wagner et al. reported an application of pcF-containing
peptides as potent, light-switchable inhibitors of the protein
tyrosine phosphatase PTP1B.83 The phosphopeptide mimetics
were found to be moderate inhibitors with Ki-values in the
micromolar range. However, irradiation of the pcF-
containing peptides with 365 nm light in the presence of
PTP1B enhanced inhibitory activity up to 120-fold.
Deactivation of PTP1B was demonstrated to proceed via an
oxidative radical mechanism and could be reverted by
addition of dithiothreitol as a reducing agent. Interestingly,
Fig. 8 Recent advances in the F2Pmp synthesis. A) Optimised
synthesis of Fmoc-F2Pmp-OH.
78 B) Copper-mediated synthesis of
AcNH-F2Pmp-OMe from an iodonium salt.
79 C) Palladium-catalyzed
difluoroalkylation of Boc-4-borono-L-phenylalanine.80
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the observed effect of PTP1B deactivation by irradiated
benzoylphosphonates without covalent labelling of the target
protein is distinct from the reported photo-crosslinking of
STAT5-SH2 domain.81
Conclusions and future perspectives
In this review we have summarized recent progress in the
synthesis of phosphotyrosine-containing compounds. Since
the discovery of tyrosine phosphorylation in 1979, pY-
containing compounds have attracted considerable attention
due to their biological relevance and importance for targeting
protein phosphorylation pathways. The last decade has seen
the emergence of commercially available pY-containing
building blocks for SPPS, which aided peptide synthesis and
almost completely superseded post-synthetic global
phosphorylation approach.
For many years the synthesis of pY-containing small
molecules has been standing on three synthetic pillars
(Scheme 1, path A–C).35 Recently, many efforts have been
made to improve these methods and develop new ones. Early
approaches of tyrosine phosphorylation using inorganic
reagents are fading away, since they require harsh conditions
and are incompatible with many functional groups. The
phosphoramidite route still dominates the field and is likely
to remain mainstream, taking into the account the
introduction of alternative tetrazole activators and numerous
commercially available phosphoramidites. However, the
phosphoramidite approach does not allow site selective
phosphorylation of a tyrosine hydroxyl group in the presence
of other hydroxyl groups. To this end, newly developed
strategies provide solutions to this problem (Scheme 2 and
Fig. 6C).16,55 The emerging aminophosphoryl chloride
approach offers not only a promising GAP synthesis,74 which
can complement the traditional SPPS, but also allows the
preparation of aryloxy triester phosphoramidate prodrugs,72
thereby expanding the phosphotyrosine prodrug toolbox.
An important aspect to consider during the multi-step
synthesis is at what step to choose to introduce the phosphate
group (or its analogues). The phosphorus containing functional
group can serve as a protecting group. Also, the presence of
phosphorus atom helps to monitor the course of a reaction by
31P NMR spectroscopy, and the reaction mixture can be
analysed without any purification or work-up. On the other
hand, the polar dialkylphosphate group can complicate the
purification of intermediates, and phosphorylation can
interfere with other functional groups in the synthesis.
pY derivatives are useful chemical tools to study protein
phosphorylation and dephosphorylation and are promising
starting points for inhibitor design. However, their use in
drug development are limited owing to enzymatic lability and
poor cell membrane permeability. To overcome these
limitations, more physiologically stable and less polar pY
mimetics have been developed, including the promising
F2pmp group. Although several approaches towards F2pmp
have been proposed, limitations remain in their synthesis
and general applicability. The introduction of a
phosphonodifluoromethyl fragment is a challenging process
and has a narrow substrate scope. Therefore, development of
methods with mild reaction conditions is much needed and
is anticipated to be an area of fertile progress in future.
The poor permeability, stability and bioavailability of pY
and F2Pmp containing molecules remain major challenges to
overcome to unlock their application as inhibitors for
Fig. 9 Benzoylphosphonates as phosphotyrosine mimetics. A) Proposed mechanism for photoactivation of 4-phosphonocarbonyl phenylalanine
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biological targets. These challenges can potentially be relaxed
and circumvented by new therapeutic modalities such as
targeted protein degradation, for example using bifunctional
small-molecule PROTACs (proteolysis targeting
chimeras).84–86 PROTACs hijack the catalytic activity of E3
ubiquitin ligases to induce ubiquitylation and subsequent
proteasomal degradation of a protein target. One of the main
advantages of using PROTAC degraders over conventional
occupancy-based inhibitors is that PROTACs can work sub-
stoichiometrically at lower concentrations, due to their
catalytic mode of action via a trimeric complex.87,88 Because
PROTACs do not require to fully occupy the target binding
site, there are less strict requirements on their cellular
permeability or binary binding affinity to the target protein
and E3 ligase.87,92 In addition, PROTAC trimeric complexes
can offer a boost in target degradation potency and selectivity
over and above what might be expected from the binding
group alone.88,89 Therefore, unoptimized pY properties, albeit
unacceptable in the context of occupancy-based inhibitors,
are predicted to be more tolerated in the context of PROTAC
degraders. Indeed, a potent STAT3 PROTAC degrader, SD-36,
based on a pY-derivative moiety was recently reported.90,91
Despite having unmasked CF2P(O)(OH)2 group, SD-36 showed
efficient cellular and in vivo activity inducing potent and
selective degradation of STAT3, which resulted in
pronounced and long-lasting tumour regression in xenograft
mouse models.90 We anticipate that the PROTAC approach
will give a new momentum to the use of pY and their
analogues, and attractive new future directions in the field.
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